SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Streiff, M. B. Search for Related Content PubMed PubMed Citation Articles by Streiff, M. B. Related Collections Hemostasis, Thrombosis, and Vascular Biology Review Articles Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 12 (June 15), 2000: pp. 3669-3677 REVIEW ARTICLE Vena caval filters: a comprehensive review Michael B. Streiff From the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.     Abstract Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References Hematologists are often asked to treat patients with venous thromboembolic disease. Although anticoagulation remains the primary therapy for venous thromboembolism, vena caval filters are an important alternative when anticoagulants are contraindicated. To assess the evidence supporting the utility of these devices, a comprehensive review of the English language literature was performed. Except for one randomized trial, the vena caval filter literature consists of case series or consecutive case series. The mean duration of follow-up for each of the 5 filter types varies from 6 to 18 months. All are about equally effective in the prevention of pulmonary embolism (2.6%-3.8%). Deep venous thrombosis (6%-32%) and inferior vena cava thrombosis (3.6%-11.2%) after filter placement vary widely among different filter types primarily because of differences in outcome assessment. Thrombosis at the insertion site is a common complication of filter placement (23%-36%). In view of the absence of randomized comparisons, no filter can be designated as superior in safety or efficacy. Vena caval filters represent a potentially important but poorly evaluated therapeutic modality in the prevention of pulmonary emboli. Randomized trials are necessary to establish the appropriate place for vena caval filters in the treatment of venous thromboembolic disease. (Blood. 2000;95:3669-3677) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References Venous thromboembolic disease is a significant cause of morbidity and mortality in the United States. Pulmonary embolism (PE), the most deadly form of venous thromboembolic disease, is diagnosed in 355 000 patients and results in as many as 240 000 deaths per year.1 In most clinical situations, anticoagulation is the preferred form of therapy. Although generally associated with a small (less than 5% per year) risk of major hemorrhage in the average patient, anticoagulation is more risky in selected patient populations (patients with thrombocytopenia, central nervous system [CNS] metastases, active gastrointestinal bleeding, and so forth).2 In these instances, vena caval filters have been considered an effective alternative form of therapy for venous thromboembolic disease. As hematologists, we are often asked to make decisions on the placement of vena caval filters. Unfortunately, the literature supporting the utility of these devices is scattered among a diverse collection of journals not typically read by many practitioners. The purpose of this comprehensive review is to summarize and critique the published data on vena caval filters and thus facilitate informed clinical decision-making by hematologists.     Methods Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References A comprehensive search of the Medline database was performed using the keywords Greenfield filter, bird's nest filter, titanium Greenfield filter, Simon nitinol filter, Vena-Tech filter, temporary vena caval filter, vena caval filter, thrombosis, deep venous thrombosis, pulmonary embolism, anticoagulation, and bleeding. Additional articles were identified by a careful review of reference lists. Study design was reviewed and data from each article were abstracted and entered into a database for analysis. Complication rates were calculated by dividing the number of patients suffering a particular complication by the population examined for that event. Patients listed as lost to follow-up or dead were not included in the denominator when calculating complication rates. None of the studies reviewed fulfilled the recently published guidelines for vena caval filter placement and patient follow-up.3     Results and discussion Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References Vena caval filter studies: stainless steel Greenfield filter Five different vena caval filters are available in the United States: the over-the-wire stainless steel alternating-hook Greenfield filter, the titanium Greenfield filter, the bird's nest filter, the Simon nitinol filter, and the Vena Tech filter (Figure 1). The over-the-wire stainless steel alternating hook Greenfield filter has recently replaced the original stainless steel Greenfield filter, because its design modifications allow easier percutaneous placement.4 Both consist of a cone-shaped array of 6 stainless steel wires, which end in hooks that secure the device in the inferior vena cava (IVC). View larger version (33K): [in this window] [in a new window]   Fig 1. Diagram of the permanent vena caval filter models. (A) The stainless steel Greenfield filter. (B) The modified-hook titanium Greenfield filter. (C) The bird's nest filter (D) The Simon nitinol filter. (E) The Vena Tech filter. Because the newer Greenfield filter has been evaluated in few patients, this review will focus on the original stainless steel Greenfield filter, which has been investigated in 40 different case series involving 3184 patients (Table 1).5-36 All the studies are case series and most are retrospective. The most common reasons for filter placement are a contraindication to anticoagulation, a complication from anticoagulation, or a failure of anticoagulation. In some series, a substantial number received filters for prophylaxis. Study populations vary from 6 to 642 participants. Serious procedural complications (eg, pneumothorax, 2 cases; cerebrovascular accident, 1 case; and death, 3 cases) are rare. The duration and intensity of the follow-up after filter placement varies considerably among studies (Table 1). In most cases, follow-up information is based on chart reviews, telephone questionnaires, or clinic visits (combined, 86% of study population). A minority of patients had radiologic surveillance (ultrasonography, 22%; computed tomography [CT] scans, 1.5%; and inferior venacavograms, 8.4%), a weakness that must be considered when reviewing event rates.                                View this table: [in this window] [in a new window]   Table 1. Compilation of vena caval filter study data The primary purpose of implanting a vena caval filter is to prevent PE. Only 66 patients suffered a PE following Greenfield filter insertion; 22 were fatal. These numbers compare favorably with anticoagulation in the management of venous thromboembolic disease.37-43 Deep venous thrombosis (DVT) developed in 6%. Only a portion of the study population was assessed for this event. Therefore, the actual DVT frequency after Greenfield filter placement is probably somewhat higher. Insertion site thrombosis (IST) is a venous thrombus that develops at the vascular access sites where filters are initially inserted. IST was identified in 87 patients. However, as with other complications of filter placement, the frequency varies with the surveillance intensity. Studies with routine ultrasound screening identified IST in 23% of participants (Table 2). Because most of these thrombi were asymptomatic, their clinical significance is unknown. Long-term follow-up studies of patients with asymptomatic IST are warranted.                                View this table: [in this window] [in a new window]   Table 2. Insertion site thrombosis rates for vena caval filters Although a less common event with current methods of venous interruption, inferior vena cava thrombosis (IVCT) remains a complication of Greenfield filter placement. Anecdotal cases of massive lower extremity swelling and phlegmasia cerulea dolens have been seen in conjunction with IVCT, occasionally with lethal consequences.44-46 More commonly, by impairing lower extremity venous drainage, IVCT predisposes patients to recurrent DVT and the postphlebitic syndrome.47,48 The venous collateral vessels that develop after IVCT also can become alternative routes for PE.49,50 In the Greenfield filter series, IVCT appears to be a rare event. Only 73 (3.6%) patients developed it during follow-up. Incomplete follow-up and the use of insensitive diagnostic techniques, however, suggest that this event may be underdiagnosed.47,51 Penetration of the IVC wall by filter prongs, migration, tilting, and fracture of filters are infrequent and predominantly asymptomatic events noted during the follow-up of patients after vena caval filter placement. Penetration of the IVC wall by the legs of a Greenfield filter has been associated with perforation of the small bowel, ureter, and aorta as well as retroperitoneal hematomas and small-bowel obstruction.52-57 Fortunately, symptomatic penetration is a rare event. Only 63 of 1448 patients (4.4%) with stainless steel Greenfield filters had evidence of IVC penetration and only 6 (0.4%) were symptomatic. Another highly publicized complication is filter migration into the heart or pulmonary arteries.58,59 Migration usually is defined as caudal or cranial movement in excess of 1 cm. Only 5.3% of patients (70 of 1329) were documented to have filter migration and clinically significant sequelae occurred in only 5 patients (0.4%). No cases of migration into the heart or pulmonary arteries were described. Occasionally, Greenfield filters tilt after placement in the IVC. In the studies reviewed, 3 of 623 filters (5.3%) were found to be tilted more than 10° from the central axis of the IVC. Theoretically, eccentric placement might be anticipated to impair performance, although no PEs have been linked to this finding.16,60-62 Five of 385 filters surveyed were noted to have fractured during follow-up. No adverse events were noted. Therefore, its significance remains unknown. Oral anticoagulants were used in 37% of patients during follow-up. The potential advantage of vena caval filters is that by virtue of their permanence, they can provide life-long protection from PE. Unfortunately, if caval thrombosis develops, this virtue also can become a liability. One potential long-term consequence of caval thrombosis or DVT is the development of the postphlebitic syndrome. Symptoms of the postphlebitic syndrome include leg swelling and ulceration. Overall, 254 patients (19%) developed postphlebitic symptoms. Given the short follow-up duration in most studies and the slow progression of postphlebitic syndrome, it is likely that this frequency is an underestimate.63,64 However, filter recipients typically have multiple reasons for developing this syndrome. Therefore, only a prospective randomized clinical trial of vena caval filters and anticoagulation with long-term follow-up will be able to determine if filters predispose patients to development of this syndrome. Titanium Greenfield filter To address concerns about venous trauma and thrombosis attributed to the stainless steel filter's large insertion catheter (29F outer diameter), Greenfield and colleagues redesigned his filter using titanium to allow the use of a smaller introducer system (14F outer diameter).65 The initial model was troubled by a tendency to migrate, tilt, and perforate the inferior vena cava.66,67 Modifications of the filter limb and hook corrected these problems and this filter, the modified-hook titanium Greenfield filter, was introduced in 1991 (Figure 1). Only studies of this version of the titanium Greenfield filter are reviewed. Ten case series were retrieved from the literature on the modified-hook titanium Greenfield filter involving 511 patients (Table 1).44,68-76 Insertion complications are unusual except for filter limb asymmetry, which was noted in 7.6% of patients (27 of 354). Filter limb asymmetry, when the distribution of filter limbs within the IVC lumen is asymmetrical, might be anticipated to impair filtration efficiency; however, no clinical sequelae have been reported.77-79 Follow-up information was available on 75% (450 of 599) of participants. More intense radiologic surveillance (abdominal radiograph, 258 of 599, 43%; ultrasound, 247 of 601, 41%; CT scans, 40 of 599, 7%) was used compared with the stainless steel Greenfield filter, but the mean follow-up duration was only 5.8 months (range, 0-81 months). The modified-hook titanium Greenfield filter appears to be as effective as the stainless steel model in preventing PE. Data on the frequency of DVT after filter placement were not routinely collected, so comparisons are difficult for this complication. Theoretically, the lower profile of the titanium Greenfield filter should result in fewer insertion site thrombi; however, the frequency (13.1%, 35 of 267) was similar to that seen with the bulkier stainless steel filter. In studies with routine IST surveillance, 28% of patients developed thrombosis (Table 2). Thus, regardless of catheter size, IST remains a frequent complication of filter placement. Inferior vena caval thrombosis occurred in 6.5% of patients with the modified-hook titanium Greenfield filter. Greater radiologic surveillance probably accounts for the higher frequency of IVCT compared with the stainless steel Greenfield filter. Postphlebitic syndrome developed in only 14% of the recipients of the titanium Greenfield filter recipients. This favorable outcome is likely a consequence of the shorter follow-up compared with the stainless-steel filter (5.8 versus 18 months). Migration (33 of 258, 12.8%) and tilting (11 of 89, 12.4%) were more common among the titanium Greenfield filter series, whereas IVC penetration (10 of 258, 3.5%) occurred at a comparable rate to the stainless steel filter. Filter fracture, which was assessed in only 1 series, was not noted in any patients. All of these events were without apparent clinical consequences. Bird's nest filter In 1984, Roehm et al80 published the initial clinical investigation of the bird's nest filter. Unlike the conical design of the Greenfield filters, the bird's nest filter consists of 4 stainless steel wires, 0.18 mm in diameter and 25 cm in length, which are affixed to the vena caval wall by V-shaped struts bearing hook-like anchors (Figure 1). Its unique design allows it to be loaded into an 14F insertion catheter and gives it the flexibility to be placed into vena cavae up to 40 mm in diameter, the largest of any filter on the market (other filters are limited to cavae of 30 mm or less).81,82 Unfortunately, the original design of the bird's nest filter had a tendency to migrate, which resulted in several deaths. Thereafter, stiffer, wider struts were used, which greatly diminished this tendency.81 Sixteen case series of the bird's nest filter exist in the English literature involving 1426 patients (Table 1).46,71,72,74,76,81,83-92 In common with all the filter literature, a mixture of prophylactic and therapeutic indications was cited as the reason for filter insertion. Study populations varied from 5 to 568 participants. Significant procedural complications were rare and compare favorably with the Greenfield filter models. A weakness of the bird's nest filter studies performed to date is the intensity of patient follow-up. The majority of the patients had clinical/chart follow-up alone (1182 of 1426, 83%). Radiologic surveillance was rare (abdominal radiograph, 166 of 1426, 12%; ultrasonography, 144 of 1426, 10%; CT scan, 76 of 1426, 5%; inferior venacavogram, 27 of 1426, 1.9%). The mean duration of follow-up was 14.2 months (0-60 months). Pulmonary emboli, DVT, and IST occurred at frequencies comparable to those with the Greenfield filter models (Tables 1 and 2). Substantial increases in the number of IST diagnosed were seen in studies using routine screening procedures. IVCT and postphlebitic syndrome developed in a minority of patients. Only 4 of 15 studies documented postphlebitic symptoms among their patients.84,87-89 Phlegmasia cerulea dolens was reported in only 2 patients after filter insertion. Filter migration (11 of 588, 1.9%) and fracture (3 of 107, 2.8%) were infrequent and asymptomatic except for migration causing the death of 1 patient. Penetration of the IVC wall was only noted in a few studies. It happened frequently (52 of 137, 37.9%) but was asymptomatic. Simon nitinol filter The Simon nitinol vena caval filter is constructed of a nickel-titanium alloy that has thermal memory properties. At 4° to 10°C, the wires, which compose the filter, are folded into a straight and compact form fitting into a 9F catheter carrier. At body temperature, the wires are programmed to unfold into an umbrella filter composed of 7 "petals" and 6 hooked legs that anchor the device in the vena cava (Figure 1). Since 1989 when the first clinical study of the Simon nitinol filter was published, it has been studied in 8 different trials comprising 319 patients (Table 1).51,72,74,76,93-96 Procedural complications are extremely rare. Difficulty releasing the filter into the IVC was noted in 1 patient (0.3%). Chart review follow-up of 99.4% (317 of 319) of the study population is available for a mean duration of 16.9 months (0-62 months). Ten percent (32 of 319) of patients had follow-up clinic visits; 31% (99 of 319) had at least 1 abdominal radiograph in follow-up. Ultrasonography was performed in 41% (132 of 319) of patients, whereas magnetic resonance imaging (MRI) and CT scans were done in 12.2% (39 of 319) and 18.2% (58 of 319), respectively. Ventilation-perfusion scans (1 of 319, 0.3%), inferior venacavograms (8 of 319, 2.5%), and intravascular ultrasound (5 of 319, 1.6%) were rarely performed. Pulmonary emboli, both fatal (1.9%) and nonfatal (10 of 265, 3.8%), were uncommon. DVT and IVCT occurred in 8.9% (11 of 123) and 11.5% (22 of 191) of patients (Tables 1 and 2). Routine surveillance for IST documented thrombosis in 31% of patients.74,76 Thrombosis of the IVC occurred in 7.7% (17 of 220) of patients. More liberal use of effective screening studies (MRI and CT scans) may be responsible for the higher rate of IVCT. Postphlebitic symptoms occurred in 12.9% (16 of 124) of the study population. Only 2 patients (0.7%) developed phlegmasia cerulea dolens after filter placement. Penetration of the IVC wall (45 of 122, 36.9%), migration (3 of 135, 2.2%), and fracture (10 of 71, 14.1%) were recorded in only a few studies; therefore, the frequency of these complications may not be accurate. Only 1 patient with IVC penetration (0.8%) was symptomatic.94 Crossed filter legs were noted in 4 of 44 participants (9.1%) in 1 study. Although theoretically this event might be predicted to impair the filter efficiency, no clinical sequelae were noted.93 Thirty-nine percent of patients received oral anticoagulants for several months after filter insertion. Vena Tech filter The Vena Tech vena caval filter is constructed of Phynox, a unique nonparamagnetic alloy (cobalt 42%, chromium 21.5%, iron 8.85%, nickel 18%, molybdenum 7.5%, magnesium 2%, and a maximum of 0.15% carbon and beryllium 0.001%). Six struts are fused into a cone-shaped filter reminiscent of the Greenfield filter. Side rails attached to the filter cone anchor it to the vena caval wall (Figure 1). Fifteen studies of the Vena Tech filter have been published involving 1050 patients (Table 1).46,48,71-73,75,76,97-104 The only common procedural complication was incomplete filter opening, which occurred in 57 of 842 participants (5.2%). In 5 patients (0.6%), a second filter had to be placed. Serious procedural complications were rare (death, myocardial infarction, and cardiac tamponade, 1 patient each). Eighty-nine percent of patients (931 of 1050) had at least telephone or chart review follow-up. Abdominal radiography was obtained in 600 (57.6%) patients; ultrasound was performed on 51% (539 of 1050). Inferior venacavograms were done in 259 patients (25%). CT scans (51 of 1050, 4.9%), ventilation-perfusion scans (46 of 1050, 4.4%), autopsies (4 of 1050, 0.4%), and venograms (2 of 1050, 0.2%) were obtained less often. The mean follow-up duration was 12 months (range, 0-81 months). Nonfatal and fatal PE occurred at comparable rates to other filters. DVT was documented in only 1 study, which identified it in 32% of participants (8 of 25).72 IST was assessed in 5 studies in which the combined rate was 16.7% (36 of 215) (Table 2).73,75,76,97,103 Thirty-six percent of patients with routine imaging had an IST diagnosed.73,76 Thrombosis of the IVC occurred in 11.2% of patients receiving the Vena Tech filter. Postphlebitic syndrome developed in 95 patients (41%). The more intense follow-up procedures used in the Vena Tech studies are probably responsible for these higher complication rates. Filter migration (55 of 661, 8.3%), tilt (30 of 640, 4.7%), and fractures (2 of 117, 1.7%) occurred infrequently and were asymptomatic in all participants. Anticoagulant use was frequent after filter placement, being present in 68% of patients at follow-up.     A randomized trial of vena caval filters Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References Until 1998, the only clinical data available on vena caval filters were derived almost exclusively from retrospective unrandomized case series. In 1998, Decousus et al105 published the first and only randomized study of vena caval filters in the prevention of PE. They randomized 400 patients using a 2 × 2 factorial design to a vena caval filter or no filter and enoxaparin or unfractionated heparin. Four different types of vena caval filters (titanium Greenfield, bird's nest, Vena Tech, and Cardial filters) were used. All were placed within 48 hours. Ventilation-perfusion scans were performed at baseline and after 8 to 12 days of anticoagulation. Vena caval filters were associated with a significant decrease in the incidence of PE compared with anticoagulation alone (1.1% versus 4.8%, P = .03) at 8 to 12 days of follow-up. After 2 years, however, this difference was no longer statistically significant although the trend still favored vena caval filters (3.4% versus 6.3%, P = .16). Symptomatic PE occurred at a similar frequency in both groups after 3 months (filter, 4; no filter, 6) (Figure 2). Fatal emboli were more common among patients treated solely with anticoagulation (0.5% versus 2.5%).105 View larger version (12K): [in this window] [in a new window]   Fig 2. Cumulative percentage of patients suffering a symptomatic pulmonary embolism at 3, 12, and 24 months of follow-up. Vena caval filters do not provide significantly greater protection against PE than anticoagulation alone. Decousus et al randomized 400 patients to receive a vena caval filter with anticoagulation or anticoagulation alone. Filters significantly reduced the incidence of PE at 8 to 12 days (P = .03). This protection was no longer significant after 2 years of follow-up (P = .16). Data adapted from Decousus et al.105 In contrast, vena caval filters were associated with significantly more recurrent DVT than anticoagulation alone (20.8% versus 11.6%, P = .02) (Figure 3). No difference in bleeding or overall mortality was documented. Sixteen of the 37 patients (43.2%) with vena caval filters who had recurrent DVT also had IVCT (8% of filter population).105 View larger version (11K): [in this window] [in a new window]   Fig 3. Cumulative percentage of patients with and without filters developing a DVT during follow-up. Vena caval filter patients have a significantly higher cumulative incidence of recurrent DVT than patients receiving anticoagulation alone. By 24 months of follow-up, significantly more filter patients had developed a DVT (P = .02). Data adapted from Decousus et al.105 In light of these data, one can conclude that vena caval filters in combination with standard anticoagulation do appear to offer significantly more protection from PE than anticoagulation alone. This additional protection, however, appears to be short-lived and does not decrease overall mortality. In addition, vena caval filters are associated with a higher incidence of recurrent DVT over 2 years of follow-up. Further follow-up of participants in this study should be highly informative, providing important information about the long-term risks and efficacy of vena caval filters in comparison with standard anticoagulation. Because almost all participants (94%) in this trial received anticoagulants for at least 3 months, however, the outcome of these patients cannot be generalized to the typical patient with a filter who does not receive anticoagulation.     Clinical controversies surrounding vena caval filters Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References Is anticoagulation necessary after vena caval filter placement? If feasible, many investigators recommend routine anticoagulation after vena caval filter placement.106,107 However, little data are available to support the utility of this practice. Several case series have attempted to address this issue.14,31-33 Although none of these investigators were able to demonstrate any benefit of anticoagulation, the retrospective, unrandomized nature of the studies as well as the limited duration and intensity of anticoagulation used in some of the studies suggest that randomized comparisons will be necessary to resolve this issue. Are vena caval filters superior to anticoagulation for treatment of venous thromboembolism? No randomized studies have been performed to address this question. The randomized study of Decousus et al105 suggests that filters may provide additional short-term protection against PE in anticoagulated patients but does not address the comparative efficacy of these therapies. An unrandomized retrospective case series found no significant differences in recurrence rate or lower extremity symptoms between the patients treated with anticoagulation and filters.36 Yet, the significant design flaws of this small study suggest that larger randomized trials will be required to answer this question conclusively. Suprarenal vena caval filters Concern about the possibility of IVCT precipitating acute renal failure has prompted many to recommend that vena caval filters be placed in the infrarenal portion of the inferior vena cava. Occasionally, however, placement below the renal veins is impossible. Six studies encompassing 187 patients have been published focusing on this subgroup (Table 3). All but 1 used Greenfield filters exclusively.5,11,108-111 Mean follow-up is 70 months. Follow-up data from chart reviews or clinic visits are available on 59%. Radiologic imaging was performed in 56%. PE occurred in 6% (7 of 112); venous insufficiency developed in 75% (55 of 73). Although IVCT was diagnosed in 3.6% (4 of 112), no evidence of significant renal morbidity was noted. Only 2 studies evaluated patients for DVT, which occurred in 3 participants (17.6%). Migration occurred in 18% (16 of 91) but all were asymptomatic.                                View this table: [in this window] [in a new window]   Table 3. Suprarenal vena caval filter studies In comparison with data on infrarenal filters, suprarenal filters appear to have a higher rate of PE and venous insufficiency. Careful inspection suggests that these events probably reflect differences in the study populations rather than filter location. The mean follow-up in the suprarenal filter studies is considerably longer than the infrarenal group (70 versus 18 months). Previous PE and malignancies were more common among the population with suprarenal filters, suggesting that this study population was at particularly high risk for further thrombotic events and venous stasis.108 Therefore, further information will be required to clarify the comparative safety of suprarenal vena caval filters. Superior vena caval filters A few investigators have published small experiences with placement of filters in the superior vena cava (SVC). These studies consist of scattered case reports and a single small case series.112-117 Thus far the results have been mixed, with some patients remaining asymptomatic and others developing SVC thrombosis. Larger patient numbers and longer, more complete follow-up will be necessary before a conclusion can be made about the safety and efficacy of SVC filters. Free-floating iliofemoral thrombus: an indication for an IVC filter? A rare but commonly proposed indication for vena caval filter placement is the presence of a free-floating iliofemoral thrombus.118 In their retrospective review of 78 patients with venographically proven iliofemoral DVT treated with anticoagulation, Norris et al119 documented an extremely high risk of PE among patients with free-floating thrombi (60%). Several other retrospective studies have reached similar conclusions.120-124 In contrast, Pacouret et al recently reported no significant difference in the occurrence of PE between patients with (3.3%) or without (3.7%) free-floating iliofemoral thrombi treated with anticoagulation.125 Although differences in study patient populations may explain these conflicting conclusions, vena caval filters have yet to be demonstrated to be superior to anticoagulation in the treatment of these patients. Vena caval filters for venous thromboembolic disease in other patient populations A number of investigators have suggested that vena caval filters should be considered as first-line therapy for DVT and PE in patients with cancer as well as prophylaxis for PE in patients after trauma and with orthopedic problems. Although a considerable amount of literature has been devoted to examining the utility of filters in these settings, none of the studies are randomized and careful follow-up is often lacking.126-129 Vena caval filters have also been endorsed for treatment of DVT and PE in patients with limited cardiopulmonary reserve, chronic obstructive pulmonary disease, postpulmonary embolectomy, after renal or cardiac transplantation, and during pregnancy.118,130 Yet, only a small number of unrandomized reports exist to support these recommendations.6,7,17,28,131,132 Because viable alternative regimens are available for all of these situations, careful assessment of the efficacy and safety of vena caval filters in these settings is necessary before firm recommendations can be made. Temporary or retrievable vena caval filters Because the long-term safety of permanent vena caval filters remains unknown and many patients have only temporary contraindications to anticoagulation, there has been considerable interest in developing effective temporary filtration devices. Several under investigation include the Tempo filter and the Gunther Tulip filter. The cone-shaped Tempo filter is attached to a catheter, which is anchored in the subcutaneous tissue at the insertion site. It can be left in place for up to 6 weeks before removal.133 Preliminary studies in Europe have demonstrated it to be safe and effective.134 The Gunther Tulip filter is a permanent vena caval filter, which can be retrieved if desired in the first 10 days after implantation. A small European study demonstrated an 80% success rate when retrieval was performed within 12 days.133,135 If proven safe and effective, these devices could be valuable tools in the treatment and prevention of venous thromboembolic disease. The risks and benefits of anticoagulation for venous thromboembolic disease Although significant safety concerns persist concerning the use of vena caval filters, an informed decision about their use must include a consideration of the risks and benefits of anticoagulation. The utility of anticoagulation in venous thromboembolic disease has been studied in numerous randomized trials involving thousands of patients worldwide. Long-term warfarin anticoagulation is associated with a rate of symptomatic recurrent thrombosis as low as 3% over 2 to 4 years of surveillance.136,137 Major hemorrhage (usually defined as an intracranial or retroperitoneal hemorrhage, one requiring a blood transfusion, or reducing baseline hemoglobin by 2 g/dL) occurs in approximately 3% of patients during heparin therapy (range, 0-7%) and 2% to 5% during subsequent warfarin anticoagulation.138,139 In patients on indefinite warfarin, Schulman et al137 noted major bleeding in 8.3% after 4 years of follow-up. A number of risk factors for bleeding have been identified, including duration of therapy, recent surgery or trauma, age above 65 years, concomitant aspirin therapy, renal or hepatic insufficiency, higher intensity therapy, previous gastrointestinal bleeding, alcohol abuse, and in some studies, malignant disease and female gender.138,139 Although these conditions increase the risk of anticoagulation, they are not viewed typically as absolute contraindications. On the other hand, most physicians would be hesitant to use anticoagulants in the setting of recent CNS trauma or hemorrhage, active bleeding, significant thrombocytopenia (less than 50 000/µL), cerebral metastases, or a recent large embolic stroke.140-142 Although scant research is available to justify these concerns, anecdotal case reports and series suggest that anticoagulation is probably sufficiently hazardous that vena caval filters should be considered for patients with venous thromboembolic disease in these situations. Indications for vena caval filter placement In light of the published data on vena caval filters and anticoagulation, what are appropriate indications for their use? Clearly, it is appropriate to consider placing a vena caval filter when an absolute contraindication to anticoagulation exists or when a life-threatening complication from anticoagulation arises. Table 4 lists some common situations that would satisfy these criteria. Failure of anticoagulation is considered by many to be a reason for vena caval filter placement. Given their adverse effects, filters should be used judiciously for this indication. Objective documentation of thrombosis in the setting of adequate anticoagulation is essential. In the setting of warfarin resistance, Trousseau syndrome must be excluded. This hypercoagulable state associated with malignancies is characterized by disseminated intravascular coagulation and recurrent arterial or venous thrombotic events. Because thrombi develop throughout the vasculature, regional therapies such as vena caval filters are ineffective and may provide a nidus for clot formation. Heparin is the only useful therapy for Trousseau syndrome.143 Numerous other indications for vena caval filter placement have been endorsed; however, definitive evidence of their superiority to conventional care for these situations is lacking (Table 5).                                View this table: [in this window] [in a new window]   Table 4. Indications for a vena caval filter                                View this table: [in this window] [in a new window]   Table 5. Proposed indications for vena caval filter placement     Conclusion Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References Since the advent of modern venous interruption with the stainless steel Greenfield filter in 1973, numerous clinical studies have been performed to assess the utility of vena caval filters in the treatment of venous thromboembolic disease. Unfortunately, virtually all of these studies have been unrandomized case series with follow-up of short duration and limited intensity. Consequently, although these devices appear to be effective in the prevention of PE, this conclusion must be considered preliminary. Furthermore, troubling concerns about the safety of these devices remain. Studies have linked filters with an increased risk of DVT, IVCT, and perhaps, postphlebitic syndrome. In the absence of randomized studies, no filter can claim superiority in effectiveness or safety over other filters or standard anticoagulation. Because long-term safety and efficacy of filters remain uncertain, use of filters should be restricted to situations in which anticoagulation is clearly contraindicated. More liberal application of vena caval filters should be restricted to prospective randomized clinical trials. Undoubtedly, vena caval filters represent an important weapon in every clinician's armamentarium for the treatment of venous thromboembolic disease, but the optimal application of this technology remains to be defined. Temporary filtration devices in clinical testing may provide many of the advantages of permanent filters without the potential long-term side effects.133,134 Carefully designed, prospective, randomized trials are needed to establish the safety and utility of both classes of vena caval filtration devices. New guidelines for vena caval filter placement and patient follow-up suggest that there is considerable interest within the clinical research community to initiate such studies.3 Until these studies are performed, the true potential and problems of vena caval filters will remain unknown.     Acknowledgments The author would like to acknowledge Michael Linkenhoker, MA, for his vena caval filter illustrations. The author also would like to thank Drs Paul Bray, Chi V. Dang, Jerry L. Spivak, and William R. Bell for their advice.     Footnotes Reprints: Michael B. Streiff, Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Ross Research Bldg, Room 1025, 720 Rutland Ave, Baltimore, MD 21205; e-mail: mstreiff{at}jhmi.edu. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Methods Results and discussion A randomized trial of... Clinical controversies... Conclusion References 1. Bick RL. Hereditary and acquired thrombophilia: preface. Semin Thromb Hemost. 1999;25:251-253[Medline] [Order article via Infotrieve]. 2. Levine M, Raskob GE, Landefeld CS, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 1998;114:511S-523S[Free Full Text]. 3. Greenfield LJ, Rutherford RB, and participants in the Vena Caval Filter Consensus Conference. Recommended reporting standards for vena caval filter placement and patient follow-up. J Vasc Interv Radiol. 1999;10:1013-1019[Medline] [Order article via Infotrieve]. 4. Cho KJ, Greenfield LJ, Proctor MC, et al. Evaluation of a new percutaneous stainless steel Greenfield filter. J Vasc Interv Radiol. 1997;8:181-187[Medline] [Order article via Infotrieve]. 5. Brenner DW, Brenner CJ, Scott J, Wehberg K, Granger JP, Schellhammer PF. Suprarenal Greenfield filter placement to prevent pulmonary embolus in patients with vena caval tumor thrombi. J Urol. 1992;147:19-23[Medline] [Order article via Infotrieve]. 6. Hux CH, Wapner RJ, Chayen B, Rattan P, Jarrell B, Greenfield L. Use of the Greenfield filter for thromboembolic disease in pregnancy. Am J Obstet Gynecol. 1986;155:734-737[Medline] [Order article via Infotrieve]. 7. Pomper SR, Lutchman G. The role of intracaval filters in patients with COPD and DVT. Angiology. 1991;42:85-89. 8. Tobin KD, Pais SO, Austin CB. Femoral vein thrombosis following percutaneous placement of the Greenfield filter. Invest Radiol. 1989;24:442-445[Medline] [Order article via Infotrieve]. 9. Welch TJ, Stanson AW, Sheedy PF II, Johnson CM, Miller WE, Johnson CD. Percutaneous placement of the Greenfield vena caval filter. Mayo Clin Proc. 1988;63:343-347[Medline] [Order article via Infotrieve]. 10. Kolachalam RB, Julian TB. Clinical presentation of thrombosed Greenfield filters. Vasc Surg. 1990;24:666-670. 11. Orsini RA, Jarrell BE. Suprarenal placement of vena caval filters: indications, techniques and results. J Vasc Surg. 1984;1:124-135[Medline] [Order article via Infotrieve]. 12. Gomez GA, Cutler BS, Wheeler HB. Transvenous interruption of the inferior vena cava. Surgery. 1983;93:612-619[Medline] [Order article via Infotrieve]. 13. Kantor A, Glanz S, Gordon DH, Sclafani SJA. Percutaneous insertion of the Kimray-Greenfield filter: incidence of femoral vein thrombosis. Am J Roentgenol. 1987;149:1065-1066[Abstract/Free Full Text]. 14. Ortega M, Gahtan V, Roberts A, Matsumoto T, Kerstein M. Efficacy of anticoagulation post-inferior vena caval filter placement. Am Surg. 1998;64:419-423[Medline] [Order article via Infotrieve]. 15. Cimochowski GE, Evans RH, Zarins CK, Lu CT, DeMeester TR. Greenfield filter versus Mobin-Uddin umbrella: the continuing quest for the ideal method of vena caval interruption. J Thorac Cardiovasc Surg. 1980;79:358-365[Medline] [Order article via Infotrieve]. 16. Greenfield LJ, Proctor MC. Twenty-year clinical experience with the Greenfield filter. Cardiovasc Surg. 1995;3:199-205[Medline] [Order article via Infotrieve]. 17. Golueke PJ, Garrett WV, Thompson JE, Smith BL, Talkington CM. Interruption of the vena cava by means of the Greenfield filter: expanding the indications. Surgery. 1988;103:111-117[Medline] [Order article via Infotrieve]. 18. Fink JA, Jones BT. The Greenfield filter as the primary means of therapy in venous thromboembolic disease. Surg Gynecol Obstet. 1991;172:253-256[Medline] [Order article via Infotrieve]. 19. Rose BS, Simon DC, Hess ML, Van Aman ME. Percutaneous transfemoral placement of the Kimray-Greenfield vena cava filter. Radiology. 1987;165:373-376[Abstract/Free Full Text]. 20. Todd GJ, Sanderson J, Nowygrod R, Benvenisty A, Reemtsma K. Recent clinical experience with the vena cava filter. Am J Surg. 1988;156:353-358[Medline] [Order article via Infotrieve]. 21. Berland LL, Maddison FE, Bernhard VM. Radiologic follow-up of vena cava filter devices. Am J Roentgenol. 1980;134:1047-1052[Abstract]. 22. Scurr JH, Jarrett PEM, Wastell C. The treatment of recurrent pulmonary embolism: experience with the Kimray-Greenfield vena cava filter. Ann R Coll Surg Engl. 1983;65:233-234[Medline] [Order article via Infotrieve]. 23. Hye RJ, Mitchell AT, Dory CE, Freischlag JA, Roberts AC. Analysis of the transition to percutaneous placement of Greenfield filters. Arch Surg. 1990;125:1550-1553[Abstract/Free Full Text]. 24. Sullivan TM, Martinez BD, Lemmon G, Clark PM, Schwartz RA, Bondy B. Clinical experience with the Greenfield filter in 193 patients and description of a new technique for operative insertion [see comments]. J Am Coll Surg. 1994;178:117-122[Medline] [Order article via Infotrieve]. 25. Alexander JJ, Yuhas JP, Piotrowski JJ. Is the increasing use of prophylactic percutaneous IVC filters justified? Am J Surg. 1994;168:102-106[Medline] [Order article via Infotrieve]. 26. Pais SO, Tobin KD, Austin CB, Queral L. Percutaneous insertion of the Greenfield inferior vena cava filter: experience with ninety-six patients. J Vasc Surg. 1988;8:460-464[Medline] [Order article via Infotrieve]. 27. Richenbacher WE, Atnip RG, Campbell DB, Waldhausen JA. Recurrent pulmonary embolism after inferior vena caval interruption with a Greenfield filter. World J Surg. 1989;13:623-628[Medline] [Order article via Infotrieve]. 28. Rohrer MJ, Scheidler MG, Wheeler HB, Cutler BS. Extended indications for placement of an inferior vena cava filter [see comments]. J Vasc Surg. 1989;10:44-49[Medline] [Order article via Infotrieve]. 29. Carabasi RA, Moritz MJ, Jarrell BE. Complications encountered with the use of the Greenfield filter. Am J Surg. 1987;154:163-168[Medline] [Order article via Infotrieve]. 30. Greenfield LJ, Peyton R, Crute S, Barnes R. Greenfield vena caval filter experience: late results in 156 patients. Arch Surg. 1981;116:1451-1456[Abstract/Free Full Text]. 31. Greenfield LJ, Michna BA. Twelve-year clinical experience with the Greenfield vena caval filter. Surgery. 1988;104:706-712[Medline] [Order article via Infotrieve]. 32. Lang W, Schweiger H, Hofmann-Preiss K. Results of long-term venacavography study after placement of a Greenfield vena caval filter. J Cardiovasc Surg. 1992;33:573-578[Medline] [Order article via Infotrieve]. 33. Jones B, Fink JA, Donovan DL, Sharp WV. Analysis of benefit of anticoagulation after placement of Kimray-Greenfield filter. Surg Gynecol Obstet. 1989;169:400-402[Medline] [Order article via Infotrieve]. 34. Braverman SJ, Battey PM, Smith RB. Vena caval interruption. Am Surg. 1992;58:188-192[Medline] [Order article via Infotrieve]. 35. Hlavaty TS, McCowan TC, Ferris EJ, Carver DL, Barnes RW. Experience with the Kimray-Greenfield inferior vena caval filter. J Ark Med Soc. 1991;88:215-217[Medline] [Order article via Infotrieve]. 36. Jones BT, Fink JA. A prospective comparison of the status of the deep venous system after treatment with intracaval interruption versus anticoagulation. J Am Coll Surg. 1994;178:220-222[Medline] [Order article via Infotrieve]. 37. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med. 1998;158:1809-1812[Abstract/Free Full Text]. 38. Anonymous. Low-molecular weight heparin in the treatment of patients with venous thromboembolism: The Columbus Investigators. N Engl J Med. 1997;337:657-662[Abstract/Free Full Text]. 39. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism: The THESEE Study group. N Engl J Med. 1997;337:663-669[Abstract/Free Full Text]. 40. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med. 1996;334:682-687[Abstract/Free Full Text]. 41. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445[Medline] [Order article via Infotrieve]. 42. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681[Abstract/Free Full Text]. 43. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982[Abstract]. 44. Harris EJJ, Kinney EV, Harris EJS, Olcott C, Zarins CK. Phlegmasia complicating prophylactic percutaneous inferior vena caval interruption: a word of caution. J Vasc Surg. 1995;22:606-611[Medline] [Order article via Infotrieve]. 45. Feinman LJ, Meltzer AJ. Phlegmasia cerulea dolens as a complication of percutaneous insertion of a vena caval filter. J Am Osteopath Assoc. 1989;89:63-68[Abstract]. 46. Magnant JG, Walsh DB, Juravsky LI, Cronenwett JL. Current use of inferior vena cava filters. J Vasc Surg. 1992;16:701-706[Medline] [Order article via Infotrieve]. 47. Tardy B, Mismetti P, Page Y, et al. Symptomatic inferior vena cava filter thrombosis: clinical study of 30 consecutive cases. Eur Respir J. 1996;9:2012-2016[Abstract]. 48. Crochet DP, Stora O, Ferry D, et al. Vena Tech-LGM filter: long-term results of a prospective study. Radiology. 1993;188:857-860[Abstract/Free Full Text]. 49. Gurewich G, Thomas DP, Rabinov KR. Pulmonary embolism after ligation of the inferior vena cava. N Engl J Med. 1966;274:1350-1354. 50. Piccone VA Jr, Vidal E, Yarnoz M, et al. The late results of caval ligation. Surgery. 1970;68:980-998[Medline] [Order article via Infotrieve]. 51. Kim D, Edelman RR, Margolin CJ, et al. The Simon nitinol filter: evaluation by MR and ultrasound. Angiology. 1992;43:541-548. 52. Miller CL, Wechsler RJ. CT evaluation of Kimray-Greenfield filter complications. Am J Roentgenol. 1986;147:45-50[Abstract/Free Full Text]. 53. Bianchini AU, Mehta SN, Mulder DS, Barkun AN, Mayrand S. Duodenal perforation by a Greenfield filter: endoscopic diagnosis. Am J Gastroenterol. 1997;92:686-687[Medline] [Order article via Infotrieve]. 54. Lang W, Schweiger H, Fietkau R, Hofmann-Preiss K. Spontaneous disruption of two Greenfield filters. Radiology. 1990;174:445-446[Abstract/Free Full Text]. 55. Dabbagh A, Chakfe N, Kretz JG, et al. Late complication of a Greenfield filter associating caudal migration and perforation of the abdominal aorta by a ruptured strut. J Vasc Surg. 1995;22:182-187[Medline] [Order article via Infotrieve]. 56. Goldman HB, Hanna K, Dmochowski RR. Ureteral injury secondary to an inferior vena caval filter. J Urol. 1996;156:1763[Medline] [Order article via Infotrieve]. 57. Goldman KA, Adelman MA. Retroperitoneal caval filter as a source of abdominal pain. Cardiovasc Surg. 1994;2:85-87[Medline] [Order article via Infotrieve]. 58. Gelbfish GA, Ascer E. Intracardiac and intrapulmonary Greenfield filters: a long-term follow-up. J Vasc Surg. 1991;14:614-617[Medline] [Order article via Infotrieve]. 59. James KV, Sobolewski AP, Lohr JM, Welling RE. Tricuspid insufficiency after intracardiac migration of a Greenfield filter: case report and review of the literature. J Vasc Surg. 1996;24:494-498[Medline] [Order article via Infotrieve]. 60. Katsamouris AA, Waltman AC, Delichatsios MA, Athanasoulis CA. Inferior vena cava filters: in vitro comparison of clot trapping and flow dynamics. Radiology. 1988;166:361-366[Abstract/Free Full Text]. 61. Thompson BH, Cragg AH, Smith TP, Bareniewski H, Barnhart WH, De Jong SC. Thrombus-trapping efficiency of the Greenfield filter in vivo. Radiology. 1989;172:979-981[Abstract]. 62. Greenfield LJ, Proctor MC. Experimental embolic capture by asymmetric Greenfield filters. J Vasc Surg. 1992;16:436-443[Medline] [Order article via Infotrieve]. 63. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423-428[Abstract/Free Full Text]. 64. Saarinen J, Sisto T, Laurikka J, et al. Late sequelae of acute deep venous thrombosis: evaluation five and ten years after. Phlebology. 1995;10:106-109. 65. Greenfield LJ, Cho KJ, Pais SO, Van Aman M. Preliminary clinical experience with the titanium Greenfield vena caval filter. Arch Surg. 1989;124:657-659[Abstract/Free Full Text]. 66. Teitelbaum GP, Jones DL, van Breda A, et al. Vena caval filter splaying: potential complication of use of the titanium Greenfield filter. Radiology. 1989;173:809-814[Abstract/Free Full Text]. 67. Ramchandani P, Koolpe HA, Zeit RM. Splaying of titanium Greenfield inferior vena caval filter. Am J Roentgenol. 1990;155:1103-1104[Free Full Text]. 68. Greenfield LJ, Cho KJ, Proctor MC, et al. Results of a multicenter study of the modified-hook titanium Greenfield filter. J Vasc Surg. 1991;14:253-257[Medline] [Order article via Infotrieve]. 69. Greenfield LJ, Proctor MC, Cho KJ, et al. Extended evaluation of the titanium Greenfield vena caval filter [published erratum appears in J Vasc Surg 1995;21:162]. J Vasc Surg. 1994;20:458-464[Medline] [Order article via Infotrieve]. 70. Thomas LA, Summers RR, Cardwell MS. Use of Greenfield filters in pregnant women at risk for pulmonary embolism. South Med J. 1997;90:215-217[Medline] [Order article via Infotrieve]. 71. Mohan CR, Hoballah JJ, Sharp WJ, Kresowik TF, Lu CT, Corson JD. Comparative efficacy and complications of vena caval filters. J Vasc Surg. 1995;21:235-245[Medline] [Order article via Infotrieve]. 72. Ferris EJ, McCowan TC, Carver DK, McFarland D. Percutaneous inferior vena caval filters: follow-up of seven designs in 320 patients. Radiology. 1993;188:851-856[Abstract/Free Full Text]. 73. Molgaard CP, Yucel EKGSC, et al. Access-site thrombosis after placement of inferior vena cava filters with 12-14F delivery sheaths. Radiology. 1992;185:257-261[Abstract/Free Full Text]. 74. Aswad MA, Sandager GP, Pais SO, et al. Early duplex scan evaluation of four vena caval interruption devices. J Vasc Surg. 1996;24:809-818[Medline] [Order article via Infotrieve]. 75. Wittenberg G, Kueppers V, Tschammler A, et al. Long-term results of vena cava filters: experiences with the LGM and the titanium Greenfield devices. Cardiovasc Interv Radiol. 1998;21:225-229[Medline] [Order article via Infotrieve]. 76. Blebea J, Wilson R, Waybill P, et al. Deep venous thrombosis after percutaneous insertion of vena caval filters. J Vasc Surg. 1999;30:821-829[Medline] [Order article via Infotrieve]. 77. Simon M, Rabkin DJ, Kleshinski S, Kim D, Ransil BJ. Comparative evaluation of clinically available inferior vena cava filters with an in vitro physiologic simulation of the vena cava. Radiology. 1993;189:769-774[Abstract/Free Full Text]. 78. Millward SF, Marsh JI, Pon C, Moher D. Thrombus-trapping efficiency of the LGM (Vena Tech) and titanium Greenfield filters in vivo. J Vasc Interv Radiol. 1992;3:103-106[Medline] [Order article via Infotrieve]. 79. Greenfield LJ, Proctor MC, Cho KJ, Wakefield TW. Limb asymmetry in titanium Greenfield filters: clinically significant? J Vasc Surg. 1997;26:770-775[Medline] [Order article via Infotrieve]. 80. Roehm JOJ. The bird's nest filter: a new percutaneous transcatheter inferior vena cava filter. J Vasc Surg. 1984;1:498-501[Medline] [Order article via Infotrieve]. 81. Roehm JOJ, Johnsrude IS, Barth MH, Gianturco C. The bird's nest inferior vena cava filter: progress report. Radiology. 1988;168:745-749[Abstract/Free Full Text]. 82. Dorfman GS. Percutaneous inferior vena caval filters. Radiology. 1990;174:987-992[Abstract]. 83. Smith JA, Atkinson NR, Walters NA, Thomson KR. Early experience with the bird's nest inferior vena-caval filter [letter]. Med J Aust. 1989;150:164-165[Medline] [Order article via Infotrieve]. 84. Thomas JH, Cornell KM, Siegel EL, Sparks C, Rosenthal SJ. Vena caval occlusion after bird's nest filter placement. Am J Surg. 1998;176:598-600[Medline] [Order article via Infotrieve]. 85. Martin B, Martyak TE, Stoughton TL, Collazo WA, Pearl W. Experience with the Gianturco-Roehm bird's nest vena cava filter. Am J Cardiol. 1990;66:1275-1277[Medline] [Order article via Infotrieve]. 86. Firkin A, Walters N, Thomson K, Atkinson N. Inferior vena cava "birds nest" filters2 year follow-up. Australas Radiol. 1992;36:286-288[Medline] [Order article via Infotrieve]. 87. Lord RS, Benn I. Early and late results after Bird's nest filter placement in the inferior vena cava: clinical and duplex ultrasound follow up. Aust N Z J Surg. 1994;64:106-114[Medline] [Order article via Infotrieve]. 88. Wojtowycz MM, Stoehr T, Crummy AB, McDermott JC, Sproat IA. The bird's nest inferior vena caval filter: review of a single-center experience. J Vasc Interv Radiol. 1997;8:171-179[Medline] [Order article via Infotrieve]. 89. Starok MS, Common AA. Follow-up after insertion of bird's nest inferior vena caval filters. Can Assoc Radiol J. 1996;47:189-194[Medline] [Order article via Infotrieve]. 90. Reed RA, Teitelbaum GP, Taylor FC, Pentecost MJ, Roehm JO. Use of the bird's nest filter in oversized inferior venae cavae. J Vasc Interv Radiol. 1991;2:447-450[Medline] [Order article via Infotrieve]. 91. Hicks ME, Middleton WD, Picus D, Darcy MD, Kleinhoffer MA. Prevalence of local venous thrombosis after transfemoral placement of a bird's nest vena caval filter. J Vasc Interv Radiol. 1990;1:63-68[Medline] [Order article via Infotrieve]. 92. Young N. Clinical follow-up of patients with percutaneously inserted inferior vena caval filters. Australas Radiol. 1995;39:233-236[Medline] [Order article via Infotrieve]. 93. Simon M, Athanasoulis CA, Kim D, et al. Simon nitinol inferior vena cava filter: initial clinical experience: work in progress. Radiology. 1989;172:99-103[Abstract/Free Full Text]. 94. Poletti PA, Becker CD, Prina L, et al. Long-term results of the Simon nitinol inferior vena cava filter. Eur Radiol. 1998;8:289-294[Medline] [Order article via Infotrieve]. 95. McCowan TC, Ferris EJ, Carver DK, Molpus WM. Complications of the nitinol vena caval filter. J Vasc Interv Radiol. 1992;3:401-408[Medline] [Order article via Infotrieve]. 96. Hawkins SP, al-Kutoubi A. The Simon nitinol inferior vena cava filter: preliminary experience in the UK. Clin Radiol. 1992;46:378-380[Medline] [Order article via Infotrieve]. 97. Murphy TP, Dorfman GS, Yedlicka JW, et al. LGM vena cava filter: objective evaluation of early results. J Vasc Interv Radiol. 1991;2:107-115[Medline] [Order article via Infotrieve]. 98. Taylor FC, Awh MH, Kahn CEJ, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991;2:435-440[Medline] [Order article via Infotrieve]. 99. Cull DL, Wheeler JR, Gregory RT, Synder SOJ, Gayle RG, Parent FN. The Vena Tech filter: evaluation of a new inferior vena cava interruption device. J Cardiovasc Surg (Torino). 1991;32:691-696[Medline] [Order article via Infotrieve]. 100. Ricco JB, Crochet D, Sebilotte P, et al. Percutaneous transvenous caval interruption with the LGM filter: early results of a multicenter trial. Ann Vasc Surg. 1988;3:242-247. 101. Ricco JB, Dubreuil F, Reynaud P, et al. The LGM Vena-Tech caval filter: results of a multicenter study. Ann Vasc Surg. 1995;9(suppl):S89-S100. 102. Millward SF, Marsh JI, Peterson RA, et al. LGM (Vena Tech) vena cava filter: clinical experience in 64 patients. J Vasc Interv Radiol. 1991;2:429-433[Medline] [Order article via Infotrieve]. 103. Millward SF, Peterson RA, Moher D, et al. LGM (Vena Tech) vena caval filter: experience at a single institution. J Vasc Interv Radiol. 1994;5:351-356[Medline] [Order article via Infotrieve]. 104. Crochet DP, Brunel P, Trogrlic S, Grossetete R, Auget JL, Dary C. Long-term follow-up of Vena Tech-LGM filter: predictors and frequency of caval occlusion. J Vasc Interv Radiol. 1999;10:137-142[Medline] [Order article via Infotrieve]. 105. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409-415[Abstract/Free Full Text]. 106. Ballew KA, Philbrick JT, Becker DM. Vena cava filter devices. Clin Chest Med. 1995;16:295-305[Medline] [Order article via Infotrieve]. 107. Kanter B, Moser KM. The Greenfield vena cava filter. Chest. 1988;93:170-175[Free Full Text]. 108. Greenfield LJ, Proctor MC. Suprarenal filter placement. J Vasc Surg. 1998;28:432-438[Medline] [Order article via Infotrieve]. 109. Greenfield LJ, Cho KJ, Proctor MC, et al. Late results of suprarenal Greenfield vena caval filter placement. Arch Surg. 1992;127:969-973[Abstract/Free Full Text]. 110. Stewart JR, Peyton JWR, Crute S, Greenfield LJ. Clinical results of suprarenal placement of the Greenfield vena cava filter. Surgery. 1982;92:1-4[Medline] [Order article via Infotrieve]. 111. Matchett WJ, Jones MP, McFarland DR, Ferris EJ. Suprarenal vena caval filter placement: follow-up of four filter types in 22 patients. J Vasc Interv Radiol. 1998;9:588-593[Medline] [Order article via Infotrieve]. 112. Owen EWJ, Schoettle GPJ, Harrington OB. Placement of a Greenfield filter in the superior vena cava. Ann Thorac Surg. 1992;53:896-897[Abstract]. 113. Ascer E, Gennaro M, Lorensen E, Pollina RM. Superior vena caval Greenfield filters: indications, techniques, and results. J Vasc Surg. 1996;23:498-503[Medline] [Order article via Infotrieve]. 114. Hoffman MJ, Greenfield LJ. Central venous septic thrombosis managed by superior vena cava Greenfield filter and venous thrombectomy: a case report. J Vasc Surg. 1986;4:606-611[Medline] [Order article via Infotrieve]. 115. Pais SO, Orchis DF, Mirvis SE. Superior vena caval placement of Kimray-Greenfield filter. Radiology. 1987;165:385-386[Abstract/Free Full Text]. 116. Black MD, French GJ, Rasuli P, Bouchard AC. Upper extremity deep venous thrombosis: underdiagnosed and potentially lethal. Chest. 1993;103:1887-1890[Abstract/Free Full Text]. 117. Lidagoster MI, Widman WD, Chevinski AH. Superior vena caval occlusion after filter insertion. J Vasc Surg. 1994;20:158-159[Medline] [Order article via Infotrieve]. 118. Jones TK, Barnes RW, Greenfield LJ. Greenfield vena caval filter: rationale and current indications. Ann Thorac Surg. 1986;42(suppl 6):S48-S55. 119. Norris CS, Greenfield LJ, Herrmann JB. Free-floating iliofemoral thrombus: a risk of pulmonary embolism. Arch Surg. 1985;120:806-808[Abstract/Free Full Text]. 120. Radomski JS, Jarrell BE, Carabasi RA, Yang S-L, Koolpe H. Risk of pulmonary embolus with inferior vena cava thrombosis. Am Surg. 1987;53:97-101[Medline] [Order article via Infotrieve]. 121. Berry RE, George JE, Shaver WA. Free-floating thrombus: a retrospective analysis. Ann Surg. 1990;211:719-723[Medline] [Order article via Infotrieve]. 122. Voet D, Afschrift M. Floating thrombi: diagnosis and follow-up by duplex ultrasound. Br J Radiol. 1991;64:1010-1014[Abstract/Free Full Text]. 123. Baldridge ED, Martin MA, Welling RE. Clinical significance of free-floating venous thrombi. J Vasc Surg. 1990;11:62-69[Medline] [Order article via Infotrieve]. 124. Monreal M, Ruiz J, Salvador R, et al. Recurrent pulmonary embolism: a prospective study. Chest. 1989;95:976-979[Abstract/Free Full Text]. 125. Pacouret G, Alison D, Pottier J-M, et al. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis: a prospective study. Arch Int Med. 1997;157:305-308[Abstract/Free Full Text]. 126. Cohen JR, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. Cancer. 1992;70:1993-1996[Medline] [Order article via Infotrieve]. 127. Rogers FB. Venous thromboembolism in trauma patients. Surg Clin North Am. 1995;75:279-291[Medline] [Order article via Infotrieve]. 128. Rodriguez JL, Lopez JM, Proctor MC, et al. Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism. J Trauma. 1996;40:797-802[Medline] [Order article via Infotrieve]. 129. Rogers FB, Shackford SR, Ricci MA, Huber BM, Atkins T. Prophylactic vena cava filter insertion in selected high-risk orthopaedic trauma patients. J Orthop Trauma. 1997;11:267-272[Medline] [Order article via Infotrieve]. 130. Bergqvist D. The role of vena caval interruption in patients with venous thromboembolism. Prog Cardiovasc Dis. 1994;37:25-37[Medline] [Order article via Infotrieve]. 131. Greenfield LJ, Scher LA, Elkins RC. KMA-Greenfield filter placement for chronic pulmonary hypertension. Ann Surg. 1979;189:560-565[Medline] [Order article via Infotrieve]. 132. Greenfield LJ, Peyton MD, Brown PP, Elkins RC. Transvenous management of pulmonary embolic disease. Ann Surg. 1974;180:461-468[Medline] [Order article via Infotrieve]. 133. Millward SF. Temporary and retrievable inferior vena cava filters: current status. J Vasc Interv Radiol. 1998;9:381-387[Medline] [Order article via Infotrieve]. 134. Bovyn G, Gory P, Reynaud P, Ricco JB. The Tempofilter: a multicenter study of a new temporary caval filter implantable for up to six weeks. Ann Vasc Surg. 1997;11:520-528[Medline] [Order article via Infotrieve]. 135. Ponchon M, Goffette P, Hainaut P. Temporary vena caval filtration: preliminary clinical experience with removable vena caval filters. Acta Clinica Belgica. 1999;54:223-228[Medline] [Order article via Infotrieve]. 136. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907[Abstract/Free Full Text]. 137. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336:393-398[Abstract/Free Full Text]. 138. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681. 139. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep venous thrombosis. Am J Med. 1999;107:414-424[Medline] [Order article via Infotrieve]. 140. Brathwaite CE, Mure AJ, O'Malley KF, Spence RK, Ross SE. Complications of anticoagulation for pulmonary embolism in low risk trauma patients. Chest. 1993;104:718-720[Abstract/Free Full Text]. 141. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Arch Intern Med. 1987;147:2177-2179[Abstract/Free Full Text]. 142. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke. 1984;15:779-789[Abstract/Free Full Text]. 143. Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau's syndrome: devastating coagulopathy in the absence of heparin. Am J Med. 1985;79:423-430[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Reconsidering anticoagulant therapy in venous thromboembolism David K. Cundiff and Michael B. Streiff Blood 2002 99: 723-724. [Full Text] [PDF] This article has been cited by other articles: M. F. Barginear, M. Lesser, M. L. Akerman, M. Strakhan, I. Shapira, T. Bradley, and D. R. Budman Need for Inferior Vena Cava Filters in Cancer Patients: A Surrogate Marker for Poor Outcome Clinical and Applied Thrombosis/Hemostasis, June 1, 2009; 15(3): 263 - 269. [Abstract] [PDF] S. M. Schellong, H. Bounameaux, and H. R. Büller CHAPTER 37 Venous Thromboembolism ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF] H. Hoppe, J. A. Kaufman, R. E. Barton, B. D. Petersen, P. C. Lakin, T. G. DeLoughery, Z. Irani, K. Yavuz, and F. S. Keller Safety of Inferior Vena Cava Filter Retrieval in Anticoagulated Patients Chest, July 1, 2007; 132(1): 31 - 36. [Abstract] [Full Text] [PDF] P. Mismetti, K. Rivron-Guillot, S. Quenet, H. Decousus, S. Laporte, M. Epinat, and F. G. Barral A Prospective Long-term Study of 220 Patients With a Retrievable Vena Cava Filter for Secondary Prevention of Venous Thromboembolism Chest, January 1, 2007; 131(1): 223 - 229. [Abstract] [Full Text] [PDF] D. E. Gerber, S. A. Grossman, and M. B. Streiff Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors J. Clin. Oncol., March 10, 2006; 24(8): 1310 - 1318. [Abstract] [Full Text] [PDF] A. C. Chiou, K. L. Biggs, and J. S. Matsumura Vena Cava Filters: Why, When, What, How? Perspectives in Vascular Surgery and Endovascular Therapy, December 1, 2005; 17(4): 329 - 339. [Abstract] [PDF] J. Ansell Vena Cava Filters: Do We Know All That We Need to Know? Circulation, July 19, 2005; 112(3): 298 - 299. [Full Text] [PDF] The PREPIC Study Group Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) Randomized Study Circulation, July 19, 2005; 112(3): 416 - 422. [Abstract] [Full Text] [PDF] G. Henkle, P. Kunz, and B. Funaki Patterns of Referral for Inferior Vena Caval Filtration: Delays and Their Impact Am. J. Roentgenol., October 1, 2004; 183(4): 1021 - 1024. [Abstract] [Full Text] [PDF] P. Augustinos and K. Ouriel Invasive Approaches to Treatment of Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-27 - I-34. [Abstract] [Full Text] [PDF] J. C. Mansour, F. T. Lee Jr, H. Chen, W. D. Turnipseed, and S. M. Weber Chronic Abdominal Pain and Upper Gastrointestinal Bleeding Due to Duodenal Perforation Caused by Migrated Inferior Vena Cava Filter: A Case Report Vascular and Endovascular Surgery, July 1, 2004; 38(4): 381 - 384. [Abstract] [PDF] J. Kelly, B.J. Hunt, R.R. Lewis, and A. Rudd Anticoagulation or Inferior Vena Cava Filter Placement for Patients With Primary Intracerebral Hemorrhage Developing Venous Thromboembolism? Stroke, December 1, 2003; 34(12): 2999 - 3005. [Abstract] [Full Text] [PDF] B. M. Alving, C. W. Francis, W. R. Hiatt, and M. R. Jackson Consultations on Patients with Venous or Arterial Diseases Hematology, January 1, 2003; 2003(1): 540 - 558. [Abstract] [Full Text] [PDF] J. Hirsh and A. Y. Y. Lee How we diagnose and treat deep vein thrombosis Blood, May 1, 2002; 99(9): 3102 - 3110. [Abstract] [Full Text] [PDF] D. K. Cundiff and M. B. Streiff Reconsidering anticoagulant therapy in venous thromboembolism Blood, January 15, 2002; 99(2): 723 - 724. [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Streiff, M. B. Search for Related Content PubMed PubMed Citation Articles by Streiff, M. B. Related Collections Hemostasis, Thrombosis, and Vascular Biology Review Articles Related Letter in Blood Online Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020